Compare RPRX & RYAAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | RYAAY |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 28.5B |
| IPO Year | 2020 | 2003 |
| Metric | RPRX | RYAAY |
|---|---|---|
| Price | $57.62 | $53.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $65.38 | ★ $67.52 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.65% | 1.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $2,378,193,000.00 | N/A |
| Revenue This Year | $47.38 | $2.38 |
| Revenue Next Year | $8.97 | $8.96 |
| P/E Ratio | $80.20 | ★ $12.60 |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $35.50 | $51.68 |
| 52 Week High | $64.38 | $74.24 |
| Indicator | RPRX | RYAAY |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 41.87 |
| Support Level | $56.36 | $51.68 |
| Resistance Level | $58.84 | $61.54 |
| Average True Range (ATR) | 1.07 | 1.14 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 61.31 | 13.09 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 daily flights across more than 220 airports in 36 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.